

# CITATION REPORT

List of articles citing

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

DOI: 10.1136/ard.2006.068676

Annals of the Rheumatic Diseases, 2007, 66, 1168-72.

**Source:** <https://exaly.com/paper-pdf/41366421/citation-report.pdf>

**Version:** 2022-10-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
353	Damage, accelerated atherosclerosis, and mortality in patients with systemic lupus erythematosus: lessons from LUMINA, a multiethnic US cohort. <b>2007</b> , 13, 350-3		12
352	[What's new in medicine in 2007?]. <b>2007</b> , 134 Suppl 1, 8S24-35		
351	New concepts in antimalarial use and mode of action in dermatology. <b>2007</b> , 20, 160-74		178
350	[Modern therapy for systemic lupus erythematosus]. <b>2007</b> , 66, 662-6, 668-71		3
349	Factores asociados a la mortalidad del lupus eritematoso sistémico. <b>2008</b> , 9, 219-234		7
348	Lessons from LUMINA: a multiethnic US cohort. <i>Lupus</i> , <b>2008</b> , 17, 971-6	2.5	18
347	[Mortality and prognostic factors in 146 patients with systemic lupus erythematosus in southern Tunisia]. <b>2008</b> , 37, 1711-6		0
346	[Hydroxychloroquine and systemic lupus: a reappraisal]. <b>2008</b> , 29, 735-7		9
345	Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. <i>Lupus</i> , <b>2008</b> , 17, 281-8	2.5	116
344	Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 829-34	2.3	73
343	Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. <i>Rheumatology</i> , <b>2008</b> , 47, 1093-6	3.8	72
342	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , <b>2008</b> , 17, 271-3	2.5	51
341	Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). <b>2008</b> , 2008, 29-30		
340	Late-onset lupus: facts and fiction. <b>2008</b> , 3, 351-356		3
339	Management of mixed connective tissue disease. <b>2008</b> , 3, 357-367		1
338	Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. <b>2008</b> , 19, 338-43		29
337	Management of cardiovascular disease risk in chronic inflammatory disorders. <b>2009</b> , 5, 208-17		44

336	Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. <i>Lupus</i> , <b>2009</b> , 18, 508-15	2.5	37
335	Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. <i>Lupus</i> , <b>2009</b> , 18, 822-30	2.5	30
334	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2009</b> , 18, 1019-25		50
333	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. <i>Rheumatology</i> , <b>2009</b> , 48, 817-22	3.8	77
332	Managing lupus patients during pregnancy. <b>2009</b> , 23, 575-82		28
331	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. <b>2009</b> , 61, 830-9		167
330	Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. <b>2009</b> , 60, 2757-66		62
329	Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?. <b>2009</b> , 61, 1284-6		3
328	Reply. <b>2009</b> , 61, 1615-1616		
327	[Antimalarials. A treatment option for every lupus patient!?.] <b>2009</b> , 68, 584, 586-90		3
326	Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair?. <b>2009</b> , 154, 61-9		9
325	Thrombosis in systemic lupus erythematosus: risk and protection. <b>2009</b> , 7, 1541-9		22
324	How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?. <b>2009</b> , 11, 129		20
323	Predictors of major infections in systemic lupus erythematosus. <b>2009</b> , 11, R109		211
322	Premature vascular damage in systemic lupus erythematosus. <b>2009</b> , 42, 580-6		23
321	Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. <b>2009</b> , 15, 111-6		31
320	Risk factors for thrombotic events in patients with systemic lupus erythematosus from different ethnic groups. <b>2009</b> , 4, 267-269		1
319	Perspectives on the management of late-onset systemic lupus erythematosus. <b>2010</b> , 6, 475-480		

318	Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues. <b>2010</b> , 12, 237-49		28
317	Lupus registries: evolution and challenges. <i>Seminars in Arthritis and Rheumatism</i> , <b>2010</b> , 39, 224-45	5.1	16
316	Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. <b>2010</b> , 77, 4-5		26
315	Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. <b>2010</b> , 62, 386-92		28
314	Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. <b>2010</b> , 62, 393-400		40
313	Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. <b>2010</b> , 62, 881-7		123
312	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <b>2010</b> , 62, 863-8		189
311	Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. <b>2010</b> , 62, 855-62		136
310	Pourquoi faut-il traiter tous les patients atteints de lupus systémique par hydroxychloroquine ?. <b>2010</b> , 77, 4-6		
309	Fundus autofluorescence and spectral domain optical coherence tomography in early detection of Plaquenil maculopathy. <b>2010</b> , 20, 785-8		13
308	Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. <b>2010</b> , 184, 2148-55		68
307	Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. <b>2010</b> , 89, 300-307		41
306	A new role for antimalarials in systemic lupus erythematosus treatment. <b>2010</b> , 5, 299-312		1
305	Systemic lupus erythematosus: safe and effective management in primary care. <b>2010</b> , 37, 767-78, vii		3
304	The role of antimalarial agents in the treatment of SLE and lupus nephritis. <b>2011</b> , 7, 718-29		159
303	Hydroxychloroquine-induced ototoxicity in a child with systemic lupus erythematosus. <b>2011</b> , 14, e1-2		7
302	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. <b>2011</b> , 14, 1-5		5
301	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. <b>2011</b> , 10, 705-14		60

300	Antimalarials and SLE. <b>2011</b> , 1061-1081		0
299	Treatment of lupus: impact on quality of life. <b>2011</b> , 13, 324-37		5
298	Systemic lupus erythematosus in Hispanics. <b>2011</b> , 44, 555-61		12
297	Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. <b>2011</b> , 7, 399-408		249
296	Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China. <b>2011</b> , 38, 1289-95		30
295	Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. <b>2011</b> , 7, 227-41		69
294	Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know. <b>2012</b> , 7, 95-107		6
293	Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. <i>Lupus</i> , <b>2012</b> , 21, 830-5	2.5	113
292	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.3	112
291	Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. <b>2012</b> , 176, 708-19		181
290	Predictors of survival in Chinese patients with lupus nephritis. <i>Lupus</i> , <b>2012</b> , 21, 1049-56	2.5	35
289	Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. <b>2012</b> , 126, 76-82		263
288	Faut-il donner des statines à tous les lupiques?. <b>2012</b> , 79, 505-510		
287	Lupus nephritis: a critical review. <b>2012</b> , 12, 174-94		164
286	Comparative safety of therapies in systemic lupus erythematosus. <b>2012</b> , 38, 795-807		1
285	Utilizing registries in systemic lupus erythematosus clinical research. <b>2012</b> , 8, 353-60		9
284	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. <b>2012</b> , 42, 968-78		72
283	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <b>2012</b> , 8, 522-33		140

282	Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. <b>2012</b> , 64, 704-12		23
281	Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. <b>2012</b> , 143, 210-21		64
280	Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. <b>2012</b> , 39, 531-5		19
279	Chloroquine: modes of action of an undervalued drug. <b>2013</b> , 153, 50-7		87
278	Th1/Th2 cytokine profile in childhood-onset systemic lupus erythematosus. <b>2013</b> , 61, 785-91		37
277	Proceedings of the 2013 Rheumatology Winter Clinical Symposia. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 42, 667-73	5.1	
276	Is there an effective treatment for late-onset systemic lupus erythematosus?. <b>2013</b> , 9, 437-450		
275	Antimalarial Medications. <b>2013</b> , 601-608		3
274	The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 77-95	5.1	202
273	Do all lupus patients need statins?. <b>2013</b> , 80, 244-9		13
272	[Treatment of systemic lupus erythematosus: myths, certainties and doubts]. <b>2013</b> , 141, 533-42		8
271	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. <b>2013</b> , 46, 363-8		22
270	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 264-72	5.1	87
269	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <b>2013</b> , 40, 831-41		75
268	Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. <b>2013</b> , 2013, 794383		16
267	Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. <i>Lupus</i> , <b>2013</b> , 22, 106-11	2.5	41
266	Systemic Lupus Erythematosus. <b>2013</b> , 803-819		
265	A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. <b>2013</b> , 43, 547-53		15

264	Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. <b>2013</b> , 68, 766-71		91
263	Pathogenesis and Treatment of Atherosclerosis in Lupus. <b>2013</b> , 341-351		2
262	Cardiovascular involvement in autoimmune diseases. <b>2014</b> , 2014, 367359		37
261	Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. <b>2014</b> , 66, 617-24		30
260	Pharmacology of Chloroquine and Hydroxychloroquine. <b>2014</b> , 35-63		59
259	Prolonged remission in SLE revisited: an old wine in a new bottle. <b>2014</b> , 41, 1728-31		2
258	Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort. <i>Rheumatology</i> , <b>2014</b> , 53, 1431-8	3.8	27
257	Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 649-57	3.8	22
256	Advances in systemic lupus erythematosus. <b>2014</b> , 42, 126-133		5
255	Treatment of Autoimmune Disease: Established Therapies. <b>2014</b> , 1209-1220		
254	Ten common mistakes in the management of lupus nephritis. <b>2014</b> , 63, 667-76		26
253	Pragmatic approaches to therapy for systemic lupus erythematosus. <b>2014</b> , 10, 97-107		63
252	Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. <b>2014</b> , 92, 124-32		32
251	Recent advances in the treatment of systemic lupus erythematosus. <b>2014</b> , 9, 89-100		
250	Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. <b>2014</b> , 193, 3803-15		37
249	Hydroxychloroquine: a multifaceted treatment in lupus. <b>2014</b> , 43, e167-80		99
248	Pathogenesis and treatment of atherosclerosis in lupus. <b>2014</b> , 40, 475-95, viii		16
247	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <b>2014</b> , 24, 751-9		32

246	Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. <b>2015</b> , 1, FSO26		18
245	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. <b>2015</b> , 67, 2176-84		84
244	Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability. <b>2015</b> , 29, 299-304		18
243	Systemic lupus erythematosus: an update on treat-to-target. <b>2015</b> , 28, 22-8		1
242	On the use and misuse of scalar scores of confounders in design and analysis of observational studies. <b>2015</b> , 34, 2618-35		4
241	Violacein Treatment Modulates Acute and Chronic Inflammation through the Suppression of Cytokine Production and Induction of Regulatory T Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0125409	3.6	16
240	Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. <b>2015</b> , 10, 365-381		14
239	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 720-9	2.5	18
238	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <b>2015</b> , 14, 358-62		80
237	A study of Thai patients with systemic lupus erythematosus in the medical intensive care unit: epidemiology and predictors of mortality. <i>Lupus</i> , <b>2015</b> , 24, 98-106	2.5	14
236	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. <b>2015</b> , 49, 317-26		76
235	Recent advances in understanding the pathogenesis of atherosclerosis in CKD patients. <b>2015</b> , 25, 205-8		6
234	Lupus in Latin-American patients: lessons from the GLADEL cohort. <i>Lupus</i> , <b>2015</b> , 24, 536-45	2.5	38
233	Atherosclerotic vascular disease in the autoimmune rheumatologic patient. <b>2015</b> , 17, 497		17
232	Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. <i>Lupus</i> , <b>2015</b> , 24, 1384-91	2.5	67
231	Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. <i>Lupus</i> , <b>2015</b> , 24, 507-15	2.5	20
230	Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. <b>2015</b> , 94, e267		32
229	Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. <b>2015</b> , 42, 2092-7		98



228	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. <b>2015</b> , 14, 1373-85		15
227	Systemic lupus erythematosus: review of synthetic drugs. <b>2015</b> , 16, 2793-806		14
226	Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. <i>Lupus</i> , <b>2015</b> , 24, 299-306	2.5	12
225	Treatment of severe lupus nephritis: the new horizon. <b>2015</b> , 11, 46-61		65
224	The Sarawak lupus cohort: clinical features and disease patterns of 633 SLE patients in a single tertiary centre from East Malaysia. <b>2015</b> , 35, 153-7		8
223	Systemic lupus erythematosus and clinical outcomes in peritoneal dialysis. <i>Lupus</i> , <b>2015</b> , 24, 290-8	2.5	3
222	Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?. <b>2015</b> , 14, 23-9		43
221	Value of Antimalarial Drugs in the Treatment of Lupus. <b>2016</b> , 515-520		
220	Current and emerging treatment options in the management of lupus. <b>2016</b> , 5, 9-20		24
219	Lupus nephritis in children - 10 years' experience. <b>2016</b> , 41, 248-254		10
218	Immunomodulators in SLE: Clinical evidence and immunologic actions. <i>Journal of Autoimmunity</i> , <b>2016</b> , 74, 73-84	14.9	51
217	Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. <b>2016</b> , 68, 1052-3		
216	Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. <b>2016</b> , 68, 1295-302		55
215	Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. <i>Rheumatology</i> , <b>2017</b> , 56, 620-628	3.8	21
214	Systemic lupus erythematosus diagnosis and management. <i>Rheumatology</i> , <b>2017</b> , 56, i3-i13	3.8	34
213	Anti-malarials: Are There Benefits Beyond Mild Disease?. <b>2016</b> , 2, 1-12		5
212	Why targeted therapies are necessary for systemic lupus erythematosus. <i>Lupus</i> , <b>2016</b> , 25, 1070-9	2.5	16
211	Application of nanoparticle technology in the treatment of Systemic lupus erythematosus. <b>2016</b> , 83, 1154-1163		19

210	Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. <b>2016</b> , 15, 1134-1140		13
209	Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. <b>2016</b> , 43, 1503-9		31
208	Systemic lupus erythematosus. <b>2016</b> , 2, 16039		390
207	Dr. Durcan, et al reply. <b>2016</b> , 43, 1255		
206	Treatment Algorithms for Patients with Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. <b>2016</b> , 68, 1385		1
205	Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumatic drugs. <b>2016</b> , 53 Suppl 1, S58-60		3
204	Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. <b>2016</b> , 68, 981-7		38
203	Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. <i>Lupus</i> , <b>2016</b> , 25, 735-40	2.5	18
202	Towards new avenues in the management of lupus glomerulonephritis. <b>2016</b> , 12, 221-34		53
201	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , <b>2016</b> , 55, 957-67	3.8	57
200	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. <b>2017</b> , 69, 252-256		7
199	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 199-203	5.1	4
198	Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. <b>2017</b> , 44, 271-278		3
197	Hydroxychloroquine retinopathy. <b>2017</b> , 31, 828-845		96
196	Hydroxychloroquine retinopathy: an emerging problem. <b>2017</b> , 31, 972-976		14
195	Epidemiology of systemic lupus erythematosus. <b>2017</b> , 13, 799-814		87
194	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <b>2017</b> , 44, 1173-1178		20
193	The gathering storm: hydroxychloroquine retinopathy screening in the U.K. <b>2017</b> , 176, 1420-1421		4

192	Predictors of incident proteinuria among patients with SLE. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000200.	4.3	12
191	Hydroxychloroquine-Induced Erythema Multiforme. <b>2017</b> , 23, 127-128		11
190	Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?. <b>2017</b> , 44, 398		49
189	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. <b>2017</b> , 76, 1176-1182		28
188	Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. <b>2017</b> , 50, 257-268		9
187	Hydroxychloroquine in systemic lupus erythematosus (SLE). <b>2017</b> , 16, 411-419		144
186	Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. <b>2017</b> , 69, 791-799		51
185	Anti-Rheumatic Therapy and Comorbidity. <b>2017</b> , 345-380		
184	The Cutaneous Spectrum of Lupus Erythematosus. <b>2017</b> , 53, 291-305		49
183	Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2005-2010	3.8	7
182	Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000209	4.3	10
181	Pharmacotherapy Pearls for the Geriatrician: Focus on Oral Disease-Modifying Antirheumatic Drugs Including Newer Agents. <b>2017</b> , 33, 1-15		3
180	Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus. <b>2017</b> , 69, 536-542		25
179	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. <b>2017</b> , 13, 35-41		19
178	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. <b>2017</b> , 617-643		0
177	Refugee Policy Implications of U.S. Immigration Medical Screenings: A New Era of Inadmissibility on Health-Related Grounds. <b>2017</b> , 14,		6
176	TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells. <b>2017</b> , 2017, 7462945		10
175	Systemic lupus erythematosus: an update. <b>2017</b> , 206, 215-220		23

174	Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000247	4.3	8
173	Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood. <b>2018</b> , 32, e4258		9
172	Systemic and Biologic Agents for Lupus Erythematosus. <b>2018</b> , 377-390		
171	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , <b>2018</b> , 57, e1-e45	3.8	142
170	Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 1853-1859	3.8	6
169	Type I interferon in rheumatic diseases. <b>2018</b> , 14, 214-228		106
168	Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. <b>2018</b> , 78, 107-114.e1		24
167	Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. <i>Lupus</i> , <b>2018</b> , 27, 722-727	2.5	35
166	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 98-103	2.3	115
165	Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. <i>Lupus</i> , <b>2018</b> , 27, 536-544	2.5	12
164	Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study. <i>Lupus</i> , <b>2018</b> , 27, 556-563	2.5	6
163	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. <b>2018</b> , 45, 90-94		10
162	Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2018</b> , 27, 753-761	2.5	8
161	Mimickers of neuropsychiatric manifestations in systemic lupus erythematosus. <b>2018</b> , 32, 623-639		5
160	Organ damage in a cohort of Colombian patients with systemic lupus erythematosus: Characterization and associated factors. <b>2018</b> , 25, 85-91		
159	Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. <b>2018</b> , 14, 693-703		96
158	An audit of the use of hydroxychloroquine in rheumatology clinics. <b>2018</b> , 2, rky013		3
157	Comment on: Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2020</b> , 59, 688-689	3.8	

156	Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. <b>2018</b> , 14, 915-931		24
155	Using hydroxychloroquine and protecting the retina. <i>Lupus</i> , <b>2018</b> , 27, 1399-1401	2.5	1
154	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <b>2018</b> , 2018, 3424136		31
153	Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000249	4.3	8
152	Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors. <b>2018</b> , 44, 371-391		11
151	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, )-Pan-American League of Associations of Rheumatology (PANLAR). <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1549-1557	2.3	56
150	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <b>2018</b> , 20, 133		26
149	[Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients]. <b>2018</b> , 145, 395-404		11
148	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. <b>2018</b> , 30, 482-489		28
147	Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. <b>2018</b> , 26, 1141-1149		42
146	The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. <b>2018</b> , 32, 1168-1173		21
145	Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2018</b> , 57, 1743-1751	3.8	20
144	Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e80	2.3	6
143	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. <i>Lupus</i> , <b>2019</b> , 28, 1101-1110	2.5	24
142	Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000321	4.3	7
141	Predictors of predominant Lupus Low Disease Activity State (LLDAS-50). <i>Lupus</i> , <b>2019</b> , 28, 1648-1655	2.5	13
140	Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. <b>2019</b> , 18, 247-254		16
139	Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption. <i>Lupus</i> , <b>2019</b> , 28, 1473-1476	2.5	5

138	Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. <i>Lupus</i> , <b>2019</b> , 28, 862-867	2.5	14
137	Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine. <b>2019</b> , 3, rkz009		7
136	Management strategies and future directions for systemic lupus erythematosus in adults. <b>2019</b> , 393, 2332-2343		119
135	Novel paradigms in systemic lupus erythematosus. <b>2019</b> , 393, 2344-2358		157
134	Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis. <i>Lupus</i> , <b>2019</b> , 28, 977-985	2.5	3
133	[Lupus nephritis]. <b>2019</b> , 60, 468-477		7
132	MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. <b>2019</b> , 39, 485-491		4
131	Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus. <i>Internal Medicine</i> , <b>2019</b> , 58, 1257-1262	1.1	10
130	Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine. <b>2019</b> , 1, 593-599		14
129	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. <b>2019</b> , 41, 476-482		10
128	Antimalarial Medications. <b>2019</b> , 650-660		
127	Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor. <b>2019</b> , 22, 468-472		2
126	Systemic lupus erythematosus: Diagnosis and clinical management. <i>Journal of Autoimmunity</i> , <b>2019</b> , 96, 1-13	14.9	153
125	Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 372-379	2.3	30
124	New therapeutic strategies in systemic lupus erythematosus management. <b>2019</b> , 15, 30-48		51
123	Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e133	2.3	2
122	Systemic Lupus Erythematosus. <b>2020</b> , 555-573		
121	Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. <b>2020</b> , 72, 448-453		48

120	Treatment of Autoimmune Disease: Established Therapies. <b>2020</b> , 1415-1435		
119	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <b>2020</b> , 72, 1800-1808		6
118	Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. <b>2020</b> , 72, 225-232		6
117	Neuropsychiatric SLE: From Immune Mechanisms to Clinical Management. <b>2020</b> ,		1
116	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <b>2020</b> , 262, 118541		4
115	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. <b>2020</b> , 34, e14118		2
114	Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?. <b>2020</b> , 216, 153086		24
113	Hydroxychloroquine shortage. <b>2020</b> , 228, 810		1
112	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. <b>2020</b> , 25,		2
111	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , <b>2020</b> , 59, v69-v81	3.8	13
110	Tracking clinical resources for coronavirus disease 2019. <b>2020</b> , 32, 441-448		2
109	The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine. <i>Lupus</i> , <b>2020</b> , 29, 1712-1718	2.5	1
108	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <b>2020</b> , 22, 191		8
107	Rheumatologists' perspective on hydroxychloroquine guidelines. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.3	1
106	Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. <b>2020</b> , 7, 433-446		26
105	Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population. <b>2021</b> , 73, 1219-1223		4
104	Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. <b>2020</b> , 87, 603-610		3
103	Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. <b>2020</b> , 9,		2

102	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. <i>Lupus</i> , <b>2020</b> , 29, 560-568	9
101	The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. <b>2020</b> , 22, 159	1
100	Investigating lupus retention in care to inform interventions for disparities reduction: an observational cohort study. <b>2020</b> , 22, 35	4
99	Serum uric acid is associated with damage in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7, e000366	4.3 2
98	Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?. <i>Lupus</i> , <b>2020</b> , 29, 671-675	2.5 1
97	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 734-736	2.3 31
96	Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. <b>2021</b> , 73, 707-716	9
95	Value of antimalarial drugs in the treatment of lupus. <b>2021</b> , 591-595	
94	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.3 18
93	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria. <b>2021</b> , 35, 343-348	6
92	Epidemiology. <b>2021</b> , 21-28	
91	Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time Trends, Health Care Utilization, and In-Hospital Mortality. <b>2021</b> , 73, 617-630	3
90	Fundus autofluorescence imaging. <b>2021</b> , 81, 100893	17
89	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. <i>Rheumatology</i> , <b>2021</b> , 60, 207-216	3.8 10
88	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. <b>2021</b> , 27, 152-171	4
87	Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. <b>2021</b> , 69, 1-14	6
86	Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. <b>2021</b> , 84, 930-937	6
85	Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine. <i>Lupus</i> , <b>2021</b> , 30, 269-279	2.5 1



84	Improving ophthalmic screening for hydroxychloroquine associated retinopathy. <b>2021</b> , 16, 133-138		
83	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <b>2021</b> , 232, 13-36		20
82	Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 1774-1783	3.8	2
81	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134		23
80	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort: The LUMINA (Lupus in Minorities: Nature vs. Nurture) Experience (LUMINA LXXXII). <b>2021</b> , 47, 55-64		
79	Studiendesign/Protokolle und Therapiesteuerung in der pädiatrischen Rheumatologie. <i>Springer Reference Medizin</i> , <b>2021</b> , 1-19	0	
78	Impact of Antimalarial Adherence on Mortality among Patients with Newly Diagnosed Systemic Lupus Erythematosus: A Population-based Cohort Study. <b>2021</b> ,		3
77	Cardiovascular disease in lupus. <b>2021</b> , 503-519		
76	Indian SLE Inception cohort for Research (INSPIRE): the design of a multi-institutional cohort. <b>2021</b> , 41, 887-894		1
75	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. <b>2021</b> ,		1
74	Predictors of Initial Hydroxychloroquine Receipt among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus. <b>2021</b> ,		1
73	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.3	2
72	Infections in systemic autoimmune diseases. <b>2021</b> , 17, 582-587		
71	CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine. <b>2021</b> ,		0
70	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <b>2021</b> ,		6
69	Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. <b>2021</b> , 12, 631869		1
68	Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251918	3.6	
67	Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.3	2

66	Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus. <b>2021</b> , 33, 18		
65	Targeted Delivery of Chloroquine to Plasmacytoid Dendritic Cells Enhances Inhibition of the Type I Interferon Response.		
64	Treatment Update in Systemic Lupus Erythematosus. <b>2021</b> , 47, 513-530		2
63	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. <i>Clinical Rheumatology</i> , <b>2021</b> , 1	3.8	3
62	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , <b>2021</b> , 30, 1790-1798	2.5	
61	Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic. <b>2021</b> , 43, 570-576		4
60	Increased IL-23R Th Cells Population Exhibits Higher SLEDAI-2K Scores in Systemic Lupus Erythematosus Patients. <b>2021</b> , 12, 690908		0
59	Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Systemic Lupus Erythematosus and Rheumatoid Arthritis: Results of a Quality Improvement Initiative. <b>2021</b> , 3, 733-737		
58	Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers.		
57	Systemischer Lupus erythematosus. <b>2021</b> , 16, 319-330		
56	Hydroxychloroquine's Early Impact on Cone Density. <b>2021</b> , 2021, 1389805		
55	Lupus und Nierenbeteiligung. 1		
54	Observance du traitement par hydroxychloroquine dans le lupus systémique : résultats contrastés et faible corrélation entre les outils d'évaluation. <b>2021</b> , 88, 369-376		
53	Antimalarial drugs (and lupus). <b>2021</b> , 601-609		
52	Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). <i>Modern Rheumatology</i> , <b>2012</b> , 22, 249-55	3.1	7
51	Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.3	4
50	Causes and Factors Associated with Frequent Hospitalization in Chinese Patients with Systemic Lupus Erythematosus: An Ambispective Cohort Study. <i>Medical Science Monitor</i> , <b>2019</b> , 25, 8061-8068	3	10
49	Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168619	3.6	13

48	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 2047-2061	5.7	4
47	Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital. <i>Internal Medicine</i> , <b>2020</b> , 59, 2485-2490 <sup>1</sup>	1.1	1
46	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 4467-4485	3.1	17
45	Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?. <i>Current Rheumatology Reviews</i> , <b>2019</b> , 15, 2-6	1.5	3
44	Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S117-S120	1.6	22
43	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. <i>Drugs in Context</i> , <b>2019</b> , 8,	5	23
42	Kollagenosen. <b>2010</b> , 99-127		
41	Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. <b>2011</b> , 17-25		
40	Treatment of non-renal lupus. <b>2011</b> , 1307-1316.e4		
39	Systemic Lupus Erythematosus in Elderly Populations. <b>2011</b> , 135-144		
38	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. <b>2012</b> , e1-e80		
37	Faut-il donner des statines à tous les lupiques ?. <b>2013</b> , 193-199		
36	Management of nonrenal and noncentral nervous system lupus. <b>2015</b> , 1099-1106		
35	Systemic Lupus Erythematosus. <b>2017</b> ,		
34	Dañ de ñgano en una cohorte de pacientes colombianos con lupus eritematoso sistñico: caracterizaciñ y factores asociados. <i>Revista Colombiana De Reumatologñ</i> , <b>2018</b> , 25, 85-91	0.2	1
33	Three Cases of Drug Discontinuation due to Adverse Events in Systemic Lupus Erythematosus Patients Administered Hydroxychloroquine. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2020</b> , 46, 146-152	0	
32	Treatment of systemic lupus erythematosus. <i>Australian Prescriber</i> , <b>2020</b> , 43, 85-90	1.3	1
31	Antipalñicos de sñntesis en dermatologñ. <i>EMC - Dermatologñ</i> , <b>2020</b> , 54, 1-11	0.1	

30	Infections in systemic autoimmune diseases. <i>Reumatologia Clínica</i> , <b>2020</b> , 17, 582-582	0.8	1
29	Damage index changes in patients with systemic sclerosis: a retrospective analysis over a five-year period. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 42-47	0.8	
28	Update on systemic lupus erythematosus pregnancy. <i>Journal of Prenatal Medicine</i> , <b>2010</b> , 4, 67-73		9
27	Targeted Delivery of Chloroquine to Antigen-Presenting Cells Enhances Inhibition of the Type I Interferon Response. <i>ACS Biomaterials Science and Engineering</i> , <b>2021</b> ,	5.2	
26	Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus. <b>2021</b> , 67-95		
25	Cardiovascular disease in systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , <b>2021</b> , 2, 157-172	0.2	
24	Indications and risk factors for hospitalization in patients with primary Sjögren syndrome: experience from a tertiary center in Turkey.. <i>Clinical Rheumatology</i> , <b>2022</b> , 1	3.8	0
23	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X211073001	3.6	0
22	RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.. <i>BMJ Open</i> , <b>2022</b> , 12, e053852	2.9	
21	Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine. <i>Future Pharmacology</i> , <b>2022</b> , 2, 92-98		
20	Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort.. <i>Lupus</i> , <b>2022</b> , 9612033221081691	2.5	
19	Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine treated systemic lupus erythematosus patients.. <i>Rheumatology</i> , <b>2022</b> ,	3.8	0
18	Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study.. <i>Rheumatology</i> , <b>2022</b> ,	3.8	
17	Quantitative autofluorescence findings in patients undergoing hydroxychloroquine treatment.. <i>Clinical and Experimental Ophthalmology</i> , <b>2022</b> ,	2.2	
16	Drug monitoring in systemic lupus erythematosus.. <i>Current Opinion in Pharmacology</i> , <b>2022</b> , 64, 102225	4.9	
15	Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9, e000682	4.3	0
14	Studiendesign/Protokolle und Therapiesteuerung in der pädiatrischen Rheumatologie. <i>Springer Reference Medizin</i> , <b>2022</b> , 183-201		0
13	Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2022</b> , 53, 310-316	1.3	

- |    |   |      |
|----|---|------|
| 12 | Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study. <i>Clinical Rheumatology</i> ,   | 3.8  |
| 11 | Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 739  | 5    |
| 10 | Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152046                  | 5.1  |
| 9  | Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications. <i>Journal of Autoimmunity</i> , <b>2022</b> , 102856                                       | 14.9 |
| 8  | Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 096120332211156  | 2.5  |
| 7  | Clock-hour topography and extent of outer retinal damage in hydroxychloroquine retinopathy. <i>Scientific Reports</i> , <b>2022</b> , 12,   | 4.7  |
| 6  | Recent Advances in SLE Treatment Including Biologic Therapies.  |      |
| 5  | How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.  |      |
| 4  | Klassifikation der Lupusnephritis.  |      |
| 3  | Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development. <b>2022</b> , 9, e000720 |      |
| 2  | Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. 096120332211159  |      |
| 1  | Good Long-Term Prognosis of Lupus Nephritis in the High-Income Afro-Caribbean Population of Martinique with Free Access to Healthcare. <b>2022</b> , 11, 4860                               |      |